Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2536 to 2550 of 7686 results

  1. Maternal and child nutrition

    In development [GID-NG10191] Expected publication date: 15 January 2025

    NICE guideline
    In development

  2. Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

    In development [GID-TA10252] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  3. Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891

    In development [GID-TA11473] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height TSID 12070

    Awaiting development [GID-TA11641] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Pridopidine for treating Huntington's disease TSID 12052

    Awaiting development [GID-TA11637] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071

    Awaiting development [GID-TA11634] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]

    In development [GID-TA11512] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  9. Artificial intelligence technologies to help detect fractures on X-rays in urgent care

    In development [GID-HTE10044] Expected publication date: 14 January 2025

    Health technology evaluations
    In development

  10. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981

    In development [GID-TA10912] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  11. Urinary Tract Infection (recurrent): antimicrobial prescribing

    In development [GID-NG10422] Expected publication date: 12 December 2024

    NICE guideline
    In development

  12. Dapagliflozin for treating chronic kidney disease [ID6411]

    In development [GID-TA11547] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments ID5082

    In development [GID-TA10969] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Delgocitinib for treating moderate to severe chronic hand eczema ID6408

    In development [GID-TA11506] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

    In development [GID-HST10061] Expected publication date: TBC

    Highly specialised technologies guidance
    In development